skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Kevin

{A1EF0A44-49EE-467F-964C-F748991F5552}

+3 year(s) experience

Kevin has been writing about pharmaceuticals for over twenty years in roles that have included online editor for PharmaTimes. After four years freelancing, which involved writing for all the principal titles in the sector, as well as consultancy work with major pharma companies, he joined Scrip in 2017.
Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Analyst Articles

Articles by Kevin

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    J&J's Spravato Set For EU Launches Soon

    23 Oct 2019

    Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

    Topic drug-approval drug-development-landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Webinar: Q1 2019 Sales and Earnings

    By Kevin Grogan 15 May 2019

    Scrip editors will dissect Q1 sales and earnings reports of top pharma companies and focus on key trends, developments, and projected future impact.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    By Kevin Grogan 07 Mar 2019

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

    Topic cell-and-gene-therapy